ErbB2/Her2 [p Tyr1248] Antibody

Immunocytochemistry/ Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] -

Immunocytochemistry/ Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Mutant ERBB2 cooperates with loss of p53 & leads to papillary GBC in recipient mice. (A) Top: Schematic of human ERBB2, indicating the location of two point mutants (S310F & V777L). Bottom: retroviral vector used to transduce organoids, that had been treated with an sgp53-containing plasmid (px459) to induce loss of p53. (B) Immunofluorescence for ERBB2 (top) & phospho-ERBB2 (bottom) on organoids harboring the indicated genetic alterations. (C) Tumor volumes 36 days after s.c. implantation of the respective organoids into recipient mice. All mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids exhibited tumor development, whereas sgp53;empty vector- & sgp53;ERBB2wildtype organoids did not give rise to tumors over a four-month observation period. There was no significant difference in the tumor burden of mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids (p = 0.999). (D) Mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids reached endpoint criteria with a median survival of 79.5 days & 58.5 days, respectively. (E) H&E & IHC for CK19 & EGFP on tumors generated with sgp53;ERBB2S310- & sgp53;ERBB2V777L organoids. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31795490), licensed under a CC-BY license. Not internally tested by Novus Biologicals.